IVEMEND

Ivemend Adverse Events Reported to the FDA Over Time

How are Ivemend adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Ivemend, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Ivemend is flagged as the suspect drug causing the adverse event.

Most Common Ivemend Adverse Events Reported to the FDA

What are the most common Ivemend adverse events reported to the FDA?

Dyspnoea	77 (7.6%)
Flushing	59 (5.82%)
Back Pain	43 (4.24%)
Hypersensitivity	41 (4.05%)
Erythema	39 (3.85%)
Nausea	31 (3.06%)
Infusion Site Pain	29 (2.86%)
Chest Pain	24 (2.37%)
Hypotension	23 (2.27%)
Chest Discomfort	21 (2.07%)
Throat Tightness	21 (2.07%)
	Show More
Feeling Hot	18 (1.78%)
Hyperhidrosis	18 (1.78%)
Infusion Site Erythema	18 (1.78%)
Loss Of Consciousness	18 (1.78%)
Pruritus	18 (1.78%)
Oxygen Saturation Decreased	17 (1.68%)
Pain In Extremity	16 (1.58%)
Infusion Site Urticaria	14 (1.38%)
Abdominal Pain	13 (1.28%)
Blood Pressure Increased	13 (1.28%)
Dizziness	13 (1.28%)
Hypertension	12 (1.18%)
Infusion Site Reaction	12 (1.18%)
Infusion Site Phlebitis	10 (.99%)
Underdose	10 (.99%)
Malaise	9 (.89%)
Syncope	9 (.89%)
Adverse Event	8 (.79%)
Anaphylactic Reaction	8 (.79%)
Death	8 (.79%)
Infusion Site Swelling	8 (.79%)
Pain	8 (.79%)
Respiratory Distress	8 (.79%)
Skin Discolouration	8 (.79%)
Anaphylactic Shock	7 (.69%)
Cardiac Arrest	7 (.69%)
Drug Hypersensitivity	7 (.69%)
Musculoskeletal Discomfort	7 (.69%)
Abdominal Discomfort	6 (.59%)
Body Temperature Decreased	6 (.59%)
Confusional State	6 (.59%)
Dystonia	6 (.59%)
Feeling Abnormal	6 (.59%)
Hallucination	6 (.59%)
Incoherent	6 (.59%)
Neoplasm Malignant	6 (.59%)
Phlebitis	6 (.59%)
Unresponsive To Stimuli	6 (.59%)
Hypokalaemia	5 (.49%)
Local Swelling	5 (.49%)
Muscle Spasms	5 (.49%)
Swelling Face	5 (.49%)
Urticaria	5 (.49%)
Vomiting	5 (.49%)
Apnoea	4 (.39%)
Blood Pressure Decreased	4 (.39%)
Bradycardia	4 (.39%)
Coma	4 (.39%)
Convulsion	4 (.39%)
Eye Rolling	4 (.39%)
Gastrointestinal Pain	4 (.39%)
Grand Mal Convulsion	4 (.39%)
Hypoxia	4 (.39%)
Inappropriate Schedule Of Drug Admi...	4 (.39%)
Incontinence	4 (.39%)
Infusion Site Oedema	4 (.39%)
Interstitial Lung Disease	4 (.39%)
Moaning	4 (.39%)
Pallor	4 (.39%)
Spider Vein	4 (.39%)
Tachycardia	4 (.39%)
Thrombosis	4 (.39%)
Vein Disorder	4 (.39%)
Visual Impairment	4 (.39%)
Agitation	3 (.3%)
Anxiety	3 (.3%)
Blood Pressure Abnormal	3 (.3%)
Hypoaesthesia Facial	3 (.3%)
Phlebitis Superficial	3 (.3%)
Photopsia	3 (.3%)
Rash	3 (.3%)
Speech Disorder	3 (.3%)
Thrombophlebitis Superficial	3 (.3%)
Abnormal Dreams	2 (.2%)
Arthralgia	2 (.2%)
Bronchospasm	2 (.2%)
Cardio-respiratory Arrest	2 (.2%)
Cardiovascular Disorder	2 (.2%)
Circulatory Collapse	2 (.2%)
Cyanosis	2 (.2%)
Deep Vein Thrombosis	2 (.2%)
Eating Disorder	2 (.2%)
Foot Deformity	2 (.2%)
Foot Fracture	2 (.2%)
Headache	2 (.2%)
Heart Rate Irregular	2 (.2%)
Hypomagnesaemia	2 (.2%)
Hyponatraemia	2 (.2%)
Hypophagia	2 (.2%)
Infusion Site Extravasation	2 (.2%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Ivemend, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ivemend is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Ivemend

What are the most common Ivemend adverse events reported to the FDA?

Respiratory	116 (11.45%)
Administration Site Reactions	97 (9.58%)
Epidermal And Dermal Conditions	80 (7.9%)
Musculoskeletal And Connective Tiss...	67 (6.61%)
Vascular	67 (6.61%)
Allergic Conditions	63 (6.22%)
Neurological	61 (6.02%)
Gastrointestinal Signs	60 (5.92%)
Decreased And Nonspecific Blood Pre...	25 (2.47%)
Cardiac And Vascular Investigations	24 (2.37%)
Medication Errors	19 (1.88%)
	Show More
Skin Appendage Conditions	18 (1.78%)
Cardiac Arrhythmias	17 (1.68%)
Metabolic, Nutritional And Blood Ga...	17 (1.68%)
Vascular Hypertensive	12 (1.18%)
Therapeutic And Nontherapeutic Effe...	11 (1.09%)
Embolism And Thrombosis	9 (.89%)
Vascular Inflammations	9 (.89%)
Fatal Outcomes	8 (.79%)
Miscellaneous And Site Unspecified ...	8 (.79%)
Movement Disorders	8 (.79%)
Seizures	8 (.79%)
Angiedema And Urticaria	7 (.69%)
Electrolyte And Fluid Balance Condi...	7 (.69%)
Vision	7 (.69%)
Anxiety Disorders	6 (.59%)
Deliria	6 (.59%)
Disturbances In Thinking	6 (.59%)
Physical Examination Topics	6 (.59%)
Cardiac Disorder Signs	5 (.49%)
Muscle	5 (.49%)
Lower Respiratory Tract Disorders	4 (.39%)
Mood Disorders	4 (.39%)
Ocular Sensory Symptoms	4 (.39%)
Urinary Tract Signs	4 (.39%)
Venous Varices	4 (.39%)
Acid-base	2 (.2%)
Appetite And General Nutritional	2 (.2%)
Bone And Joint Injuries	2 (.2%)
Bone, Calcium, Magnesium And Phosph...	2 (.2%)
Bronchial Disorders	2 (.2%)
Eating Disorders	2 (.2%)
Gastrointestinal Neoplasms Malignan...	2 (.2%)
Headaches	2 (.2%)
Injuries	2 (.2%)
Joint	2 (.2%)
Musculoskeletal And Connective Tiss...	2 (.2%)
Ocular Infections, Irritations And ...	2 (.2%)
Oral Soft Tissue Conditions	2 (.2%)
Procedural And Device Related Injur...	2 (.2%)
Reproductive Tract	2 (.2%)
Respiratory And Mediastinal Neoplas...	2 (.2%)
Sleep Disorders	2 (.2%)
Body Temperature Conditions	1 (.1%)
Gastrointestinal Ulceration And Per...	1 (.1%)
Infections - Pathogen Unspecified	1 (.1%)
Lifestyle Issues	1 (.1%)
Ocular Neuromuscular	1 (.1%)
Peritoneal And Retroperitoneal Cond...	1 (.1%)
Upper Respiratory Tract Disorders	1 (.1%)
Vascular Hemorrhagic	1 (.1%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Ivemend, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ivemend is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.